Resultados a corto plazo del tratamiento con 131I en pacientes con bocio multinodular: influencia del grado de hipertiroidismo asociado y otras variables / Short-term results of treatment with 131I in patients with multinodular goiter: effect of the associated degree of hyperthyroidism and other variables

Objetivo. Evaluar la efectividad del tratamiento con radioyodo y la incidencia de hipotiroidismo posterior en pacientes con hipertiroidismo subclínico o hipertiroidismo clínico asociado a bocio multinodular (BMN). Métodos. Estudio retrospectivo de 69 pacientes consecutivos con BMN tratados con 131I, con una dosis fija ponderada de 16 mCi (592 MBq), durante el año 2008 y seguidos durante seis meses. Se clasificaron en dos grupos: hipertiroidismo subclínico e hipertiroidismo clínico. Comparamos la tasa de éxito y la incidencia de hipotiroidismo. Resultados. En el 82,09% de los pacientes se corrigió la disfunción tiroidea; entre los pacientes con hipertiroidismo clínico la proporción fue del 100% y con hipertiroidismo subclínico del 78,13% (p=0,105). La incidencia global de hipotiroidismo fue de 16,42%; 25,00% entre los que presentaban hipertiroidismo clínico y 14,55% entre los hipertiroidismos subclínicos (p=0,400). No se encontraron diferencias estadísticamente significativas al analizar los resultados según el grado de descenso de TSH en los pacientes con hipertiroidismo subclínico. Siete individuos presentaron anticuerpos antiperoxidasa tiroidea (anti-TPO) antes del tratamiento; la incidencia de hipotiroidismo fue superior en ellos (57,14% vs 11,67%; p=0,011). La prevalencia de arritmias cardiacas fue cuatro veces mayor en el grupo de hipertiroidismo clínico. El tratamiento previo con tiamazol afectó de manera positiva a los resultados. Conclusiones. Una dosis fija ponderada de 131I es altamente efectiva y segura para el control del hipertiroidismo clínico y subclínico asociado al BMN. Los pacientes con anticuerpos anti-TPO positivos parecen tener un elevado riesgo de desarrollar hipotiroidismo postyodo(AU)

Objective. To assess the effectiveness of radioactive iodine (RAI) therapy and the incidence of hypothyroidism post RAI in patients with subclinical hyperthyroidism or clinical hyperthyroidism with Multinodular Goiter (MNG). Methods. A retrospective study of 69 consecutive patients treated with 131I for MNG during the year 2008 observed for six months. All patients received a single fixed dose of 16 mCi (592 MBq) weighted by the gland size. They were categorized into two groups: subclinical hyperthyroidism or clinical hyperthyroidism. We compared the success rate and the incidence of hypothyroidism. Results. The thyroid dysfunction was corrected in 82.09% of the patients. Success rate was 100% in the clinical hyperthyroidism group and 78.13% in the subclinical hyperthyroidism group (P=0.105). The overall incidence of hypothyroidism was 16.42%; 25.00% of patients with clinical hyperthyroidism and 14.55% with subclinical hyperthyroidism developed this secondary effect (P=0.400). No statistically significant differences were found in the success rate in the incidence of hypothyroidism when the results were analyzed according to the thyrotropin decrease in patients with subclinical hyperthyroidism. Seven patients had positive anti-thyroid peroxidase antibodies (anti-TPO) before therapy. The incidence of hypothyroidism was significantly higher in them (57.14% vs 11.67%; P=0.011). Cardiac arrhythmias were four times more frequent in patients with clinical hyperthyroidism. Previous treatment with thiamazol positively affected the outcome. Conclusions. A single fixed weighted dose of 131I is highly effective and safe for the control of clinical and subclinical hyperthyroidism due to MNG. Patients with anti-TPO antibodies may have a high risk of developing post-iodine hypothyroidism(AU)

[Short-term results of treatment with 131I in patients with multinodular goiter: effect of the associated degree of hyperthyroidism and other variables]. / Resultados a corto plazo del tratamiento con 131I en pacientes con bocio multinodular: influencia del grado de hipertiroidismo asociado y otras variables.

OBJECTIVE: To assess the effectiveness of radioactive iodine (RAI) therapy and the incidence of hypothyroidism post RAI in patients with subclinical hyperthyroidism or clinical hyperthyroidism with Multinodular Goiter (MNG). METHODS: A retrospective study of 69 consecutive patients treated with (131)I for MNG during the year 2008 observed for six months. All patients received a single fixed dose of 16 mCi (592 MBq) weighted by the gland size. They were categorized into two groups: subclinical hyperthyroidism or clinical hyperthyroidism. We compared the success rate and the incidence of hypothyroidism. RESULTS: The thyroid dysfunction was corrected in 82.09% of the patients. Success rate was 100% in the clinical hyperthyroidism group and 78.13% in the subclinical hyperthyroidism group (P=0.105). The overall incidence of hypothyroidism was 16.42%; 25.00% of patients with clinical hyperthyroidism and 14.55% with subclinical hyperthyroidism developed this secondary effect (P=0.400). No statistically significant differences were found in the success rate in the incidence of hypothyroidism when the results were analyzed according to the thyrotropin decrease in patients with subclinical hyperthyroidism. Seven patients had positive anti-thyroid peroxidase antibodies (anti-TPO) before therapy. The incidence of hypothyroidism was significantly higher in them (57.14% vs 11.67%; P=0.011). Cardiac arrhythmias were four times more frequent in patients with clinical hyperthyroidism. Previous treatment with thiamazol positively affected the outcome. CONCLUSIONS: A single fixed weighted dose of (131)I is highly effective and safe for the control of clinical and subclinical hyperthyroidism due to MNG. Patients with anti-TPO antibodies may have a high risk of developing post-iodine hypothyroidism.